Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in neutron capture therapy.

R G Fairchild1, F Wheeler, D N Slatkin

  • 1Brookhaven National Laboratory, Upton, New York.

Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|April 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Radiologic Grading System for Assessing the Radiographic Outcome of Treatment in Lymphatic and Lymphatic-Venous Malformations of the Head and Neck.

AJNR. American journal of neuroradiology·2021
Same author

New detection configuration for low activity levels of PET tracers during the analysis of plasma samples.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2019
Same author

Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.

Oral oncology·2019
Same author

Studies of aluminum in rat brain.

Biological trace element research·2013
Same author

The trypanocidal activity of amidine compounds does not correlate with their binding affinity to Trypanosoma cruzi kinetoplast DNA.

Antimicrobial agents and chemotherapy·2011
Same author

Micro-CT enables microlocalisation and quantification of Her2-targeted gold nanoparticles within tumour regions.

The British journal of radiology·2010
Same journal

Effects of intrafractional motion on targeting accuracy in frameless single-isocenter multi-target stereotactic radiosurgery.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same journal

[Evolution of metastases in non-small-cell lung cancer: preliminary results from the TRACERx-PEACE study].

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same journal

[SAKK 09/10: dose-intensified salvage radiotherapy for biochemical recurrence after prostatectomy-no benefit, but additional toxicity?]

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same journal

Helical intensity-modulated radiation therapy vs. C-arm-based volumetric modulated arc therapy for sinonasal tumours: organ at risk sparing and treatment efficiency.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same journal

Delta radiomics for predicting early radiation-induced lung injury after thoracic radiotherapy: a retrospective paired-CT study.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same journal

Individualized radiotherapy of bone metastases from prostate cancer: time trends and 5-year survival results.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
See all related articles

Clinical trials for neutron capture therapy are advancing in the U.S. with new reactor developments and improved boron compounds for treating deep tumors. Future treatments may use targeted antibodies and fractionated therapy for better results.

Area of Science:

  • Nuclear Medicine
  • Radiation Oncology
  • Medical Physics

Background:

  • Neutron capture therapy (NCT) is an investigational cancer treatment.
  • Advancements in reactor technology and boron compound development are crucial for NCT.
  • Clinical trials are being planned at multiple U.S. research reactors.

Purpose of the Study:

  • To review the conditions for initiating clinical trials of neutron capture therapy in the U.S.
  • To highlight technical developments at key U.S. research reactors for NCT.
  • To discuss the evolution of boron delivery compounds for enhanced therapeutic efficacy.

Main Methods:

  • Review of technical developments at Brookhaven Medical Research Reactor (BMRR), Power Burst Facility (PBF), Massachusetts Institute of Technology Reactor (MITR), and Georgia Institute of Technology Research Reactor (GTRR).

Related Experiment Videos

  • Focus on developing epithermal neutron beams with fluxes of 10(9) to 10(10) n/cm2s.
  • Evaluation of boron concentrations in tumors (approx. 35 µg 10B/g) and tumor/normal tissue ratios (approx. 10).

    • Main Results:

    • Expected therapeutic dose gains of 2-4, depending on fast neutron dose suppression.
    • Identification of next-generation boron compounds, including p-boronophenylalanine and boronated porphyrins, for improved tumor targeting.
    • Potential for tumor cell-specific boronated monoclonal antibodies as a highly promising future approach.

    Conclusions:

    • Clinical trials for NCT are feasible with current technical advancements in the U.S.
    • Future NCT protocols will likely involve fractionated treatment schemes.
    • The development of targeted boron delivery agents is key to optimizing NCT outcomes.